Skip to main content
Clinical Trials/CTRI/2020/07/026675
CTRI/2020/07/026675
Not yet recruiting
Phase 1

Randomized controlled Clinical Trial of Ayurveda Treatment Protocol with spice mix tablet (Tulsimmune) for management of SARS-CoV-2 Infection (COVID-19)â??.

Suraj Ayurveda Clinic and Research center0 sites0 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Suraj Ayurveda Clinic and Research center
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Suraj Ayurveda Clinic and Research center

Eligibility Criteria

Inclusion Criteria

  • 1\.Age Eligible for Study:18 Years to 75, male female
  • 2\.Subject must meet the WHO/MOHFW India /ICMR Criteria having symptoms of SARS CoV2 described in WHO Report/groups described by MOHFW India, (Group B,C,D,E mainly)
  • 3\.Quarantine/non hospitalized or hospitalized AND Fulfills WHO case definition, including a positive PCR for COVID\-19 from any specimen (e.g. respiratory, blood, urine, stool, other bodily fluid) and other analysis.

Exclusion Criteria

  • 1\.Active indication and use for one of the investigational products (e.g. HIV positive or active hepatitis B if antiretroviral agents were used )
  • 2\.Allergy or other contraindication or one of the investigational products
  • 3\.In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
  • 4\.Participant with any immunosuppressive condition or hematological disease
  • 5\.Participation in any other A.S.U and H protocol
  • 6\.Pregnant woman and lactating mother

Outcomes

Primary Outcomes

Not specified

Similar Trials